問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of Hematology & Oncology

Division of General Internal Medicine

National Taiwan University Hospital Hsin-Chu Branch (在職)

Division of Hematology & Oncology

Division of General Internal Medicine

更新時間：2023-09-19

劉宗灝LIU, TSUNG-HAO
  • Principal Investigator
  • Clinical Trial Experience (year) 12 years 9 個月

  • thliu@ntuh.gov.tw

Recruiting Trial

97Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

劉宗灝

List

115Cases

2025-06-25 - 2030-03-31

Phase II

Not yet recruiting
A Phase 2, Randomized, Open-Label Study Comparing Telisotuzumab Adizutecan (ABBV-400) Monotherapy to the Current Standard of Care in Subjects with Post Adjuvant ctDNA Positive Colorectal Cancer and No Radiographic Evidence of Disease (NED)

  • Condition/Disease

    ctDNA-positive colorectal cancer (CRC)

  • Test Drug

    ABBV-400

Participate Sites
3Sites

Recruiting3Sites

2022-07-06 - 2025-05-31

Others

Active
An Open-label Study of E7386 in Combination With Other Anticancer Drug(s) in Subjects With Solid Tumors

  • Condition/Disease

    Endometrial Neoplasms

  • Test Drug

    Tablets Capsules

Participate Sites
6Sites

Terminated6Sites

2020-09-30 - 2029-01-09

Phase I/II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2025-10-01 - 2029-06-30

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2023-08-01 - 2029-01-17

Phase III

Active
A Phase 3, Open-Label, Randomized Study of Perioperative Dostarlimab Monotherapy Versus Standard of Care in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer

  • Condition/Disease

    Untreated T4N0 or stage III mismatch repair-deficient (dMMR)/microsatellite instability-high (MSI-H) resectable colon cancer

  • Test Drug

    JEMPERLI 500 mg concentrate for solution for infusion

Participate Sites
4Sites

Not yet recruiting1Sites

Recruiting3Sites

2022-09-01 - 2026-08-31

Others

Active

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2020-01-01 - 2025-12-31

IIT

Phase II

Active
A Phase II Study of Durvalumab (MEDI 4736) for Advanced Hepatocellular Carcinoma in Patients With Active Chronic Hepatitis B Virus Infection

  • Condition/Disease

    Active Chronic Hepatitis B Virus Infection

  • Test Drug

    IMFINZI injection

Participate Sites
3Sites

Not yet recruiting2Sites

Recruiting1Sites

2019-12-01 - 2022-12-31

Phase II

Completed
A Study of Nivolumab Combination Gemcitabine and S1 as the First-Line Treatment in Patients With Advanced Biliary Tract Cancer

  • Condition/Disease

    Advanced Biliary Tract Cancer

  • Test Drug

    OPDIVO

Participate Sites
7Sites

Recruiting7Sites

2025-09-24 - 2028-11-30

Phase I

Not yet recruiting
A First-In-Human, Phase 1, Open-Label, Multicenter Study of ZW251, a Novel Glypican-3 Targeting Antibody-Drug Conjugate, in Participants with Advanced Solid Tumors, Including Hepatocellular Carcinoma

  • Condition/Disease

    Advanced Solid Tumors, Including Hepatocellular Carcinoma

  • Test Drug

    ZW251

Participate Sites
3Sites

Recruiting3Sites

2023-03-01 - 2026-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

1 3 4 5 6 7 12
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB